Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators. - Wikidata - wikimedia - TriplyDB

Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.

Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.

http://www.wikidata.org/entity/Q34134678

about

Discovery of ML326: The first sub-micromolar, selective M5 PAM Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia Selective syntheses of no-carrier-added 2- and 3-[18F]fluorohalopyridines through the radiofluorination of halopyridinyl(4'-methoxyphenyl)iodonium tosylates.Room-Temperature Direct β-Arylation of Thiophenes and Benzo[b]thiophenes and Kinetic Evidence for a Heck-type Pathway Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges.Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists.Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe.Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012.M1 muscarinic cetylcholine receptor allosteric modulators as potential therapeutic opportunities for treating Alzheimer's disease

P2860

Q28288485-E68D3BAD-A8BE-44EC-AD7E-C3A5420EAC31 Q30446914-E21F3BBD-F702-4DC6-827E-6AB9BA3122E8 Q30459624-803646B5-5D6B-4F2E-BF01-39C3698652DE Q34284995-DAD212C2-9E0B-46FD-8A6A-CF04E697FC02 Q34509995-0BDB6C7D-B0AF-4FDC-933D-BD413C0B503E Q35534556-1D4BBBBD-77DA-4443-802E-8E242A580C0A Q35952381-CA7F92AE-45B8-4E27-86D2-162CE35AEBE1 Q36912560-E6385E7A-FF7C-4C75-9A78-A586FF94A40A Q38070176-BAB486B6-D8E5-431F-9618-564DC6D2545A Q41594414-B86ECE10-78ED-4C0F-9154-5F520C9BB1F8 Q41828999-26F19C89-F1AD-4B74-8C64-7120D15B0A66 Q41855867-B10FCC3C-26A2-4426-8FC2-D6017EA31B02 Q42323359-85CED36B-3171-4006-8AB9-67C941396864 Q58856223-5BA45431-6513-405C-BD04-AC7370D07D19

P2860

Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.

http://www.wikidata.org/entity/Q34134678

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.

@ast

Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.

@en

Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.

@nl

type

label

Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.

@ast

Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.

@en

Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.

@nl

prefLabel

Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.

@ast

Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.

@en

Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.

@nl

P1433

Q34134678-626E1DF2-E53B-4B73-921B-BB88B7E7FA81

P1476

Q34134678-F04DDFB1-2F42-4927-94D9-8E9C0AA93242

P2093

Q34134678-2DF195B0-16AD-4B31-95DB-4066E9FFB54B

Q34134678-61F53738-B65A-47AB-AD88-FB6F92A988E7

Q34134678-80A967D0-F6E4-4584-B387-F2CBBA59BD89

P2860

Q34134678-08E41145-AD08-4061-B9D3-E5221643C8BD

Q34134678-1E8E3B06-BF9D-4808-AE65-AECA885B69CE

Q34134678-289C1F55-CBE9-4FB3-BD19-D2437E40F1CB

Q34134678-3CAC6781-B991-41A1-91D1-5038042957D9

Q34134678-4C3BB21E-39B2-4D2A-A610-D91F3E917B46

Q34134678-5C60A341-9389-4FC5-B20F-76742F34E418

Q34134678-5CF089C4-524B-42D3-8DB5-AB6D74C1216D

Q34134678-5DCBD482-94C7-42B3-9BB3-D394956E4988

Q34134678-62884C31-E8A6-4431-9F49-F0EB3A45878E

Q34134678-65B95796-BAE7-4C43-AA67-864208C7CD98

P304

Q34134678-4FA2A735-B3B1-4B6B-8ADA-A4556450CB80

P31

Q34134678-552F8784-65CB-4673-875B-33F255D5E7F2

P356

Q34134678-6E87B803-6185-4EE1-8732-2E04767FD2AD

P407

Q34134678-9BE4EBB9-42D7-4E36-BC5F-AE9D1EA42FB9

P433

Q34134678-CDDF1981-80EA-4B36-8694-BC9E311C6FBD

P478

Q34134678-A5890D50-2C1D-4338-94D3-95338F7BB621

P50

Q34134678-6975E79B-AB22-4B99-A9E7-1BE9FE7A5709

Q34134678-C8D4A6D2-F926-4BC5-B4EF-FCB206D66333

P577

Q34134678-9A8BC6FC-C108-4FD1-9A3A-D84F9A6298F3

P5875

Q34134678-4D444B27-BF35-481E-BEF8-12619BD1E23C

P698

Q34134678-C7B33461-06FA-484E-9D4B-7A7D522C8383

P932

Q34134678-A147622F-A78F-446E-8E06-01711B9D225F

P356

J.BMCL.2010.08.042

P1433

Bioorganic & Medicinal Chemistry Letters

P1476

Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.

@en

P2093

Corey R Hopkins

http://www.w3.org/2001/XMLSchema#string

J Phillip Kennedy

http://www.w3.org/2001/XMLSchema#string

Thomas M Bridges

http://www.w3.org/2001/XMLSchema#string

P2860

Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders

Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAM

Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs)

Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats

Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity.

Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins

Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4

Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties

Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas--the effect of capping the distal basic piperidine nitrogen.

P304

5617-5622

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BMCL.2010.08.042

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Craig W. Lindsley

P577

2010-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46035956

http://www.w3.org/2001/XMLSchema#string

P698

20801651

http://www.w3.org/2001/XMLSchema#string

P932

3179183

http://www.w3.org/2001/XMLSchema#string